Quince Therapeutics (QNCX) Cash & Equivalents (2018 - 2026)

Quince Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 46.84% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 46.84% YoY), while the FY2025 annual figure was $4.4 million, up 75.38% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $3.0 million, down from $4.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $67.6 million in Q1 2022, with the low at $2.5 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $20.8 million (2023), against an average of $24.6 million.
• Peak annual rise in Cash & Equivalents reached 141.2% in 2025, while the deepest fall reached 91.42% in 2025.
• Quince Therapeutics' Cash & Equivalents stood at $44.6 million in 2022, then tumbled by 53.45% to $20.8 million in 2023, then sank by 87.9% to $2.5 million in 2024, then jumped by 75.38% to $4.4 million in 2025, then sank by 31.35% to $3.0 million in 2026.
• Business Quant data shows QNCX's Cash & Equivalents at $3.0 million in Q1 2026, $4.4 million in Q4 2025, and $6.5 million in Q3 2025.